Weak On High Volume: OpGen (OPGN)

Trade-Ideas LLC identified OpGen (OPGN) as a weak on high relative volume candidate
By TheStreet Wire ,

Trade-Ideas LLC identified

OpGen

(

OPGN

) as a weak on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified OpGen as such a stock due to the following factors:

  • OPGN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $6.9 million.
  • OPGN has traded 1.9 million shares today.
  • OPGN is trading at 876.88 times the normal volume for the stock at this time of day.
  • OPGN is trading at a new low 13.24% below yesterday's close.

'Weak on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as material stock news, analyst downgrades, insider selling, selling from 'superinvestors,' or that hedge funds and traders are piling out of a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize (or avoid losses by trimming weak positions). In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in OPGN with the Ticky from Trade-Ideas. See the FREE profile for OPGN NOW at Trade-Ideas

More details on OPGN:

OpGen, Inc. engages in developing and deploying precision medicine tools to combat infectious disease in global healthcare settings. OPGN has a PE ratio of 1. Currently there is 1 analyst that rates OpGen a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for OpGen has been 59,900 shares per day over the past 30 days. OpGen has a market cap of $19.8 million and is part of the health care sector and health services industry. Shares are up 94.7% year-to-date as of the close of trading on Wednesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates OpGen as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and weak operating cash flow.

Highlights from the ratings report include:

  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 73.6% when compared to the same quarter one year ago, falling from -$2.60 million to -$4.51 million.
  • Net operating cash flow has significantly decreased to -$3.80 million or 121.08% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
  • The current debt-to-equity ratio, 0.47, is low and is below the industry average, implying that there has been successful management of debt levels. Although the company had a strong debt-to-equity ratio, its quick ratio of 0.98 is somewhat weak and could be cause for future problems.
  • Compared to other companies in the Biotechnology industry and the overall market, OPGEN INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • OPGN's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 65.85%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Loading ...